DHR Health Urology Institute Expands Expertise with Dr. Kayvon Kian

Translate to Spanish or other 102 languages!

DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Kayvon Kiani to our esteemed team at the DHR Health Urology Institute.  Courtesy image. Bgd for illustration purposes
DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Kayvon Kiani to our esteemed team at the DHR Health Urology Institute. Courtesy image. Bgd for illustration purposes
- Advertisement -

EDINBURG, Texas – DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Kayvon Kiani to our esteemed team at the DHR Health Urology Institute. Kiani looks forward to serving the people of the Rio Grande Valley by providing advanced care for urinary and pelvic conditions, including kidney stones, enlarged prostate, and cancers of the kidney, bladder, and prostate. He specializes in minimally invasive approaches and advanced surgical techniques to help patients achieve the best possible outcomes.

“We are proud to welcome Dr. Kiani back to the DHR Health family,” said Marissa Castañeda, senior executive vice president at DHR Health. “His extensive training and dedication to patient care will strengthen the services we provide to our community. We look forward to the positive impact he will have on the lives of patients across the Rio Grande Valley.”

Kiani earned his undergraduate degree from Northwestern University in Illinois, and his medical degree from the Medical College of Wisconsin in Milwaukee, Wisconsin. He completed a general surgery internship at the University of Colorado Hospital in Aurora, Colorado, followed by a urologic surgery residency at the same institution, where he gained extensive training in the latest techniques in urologic care.

- Advertisement -

In addition to his clinical training, Kiani has contributed to research in urologic surgery and has presented at national and international conferences, including the American Urological Association and the World Congress of Endourology and Uro-Technology. He is an active member of the American Medical Association, American Urological Association, and the South Central Section of the American Urological Association.

“I am grateful for the opportunity to care for the people of the Rio Grande Valley,” said Kiani. “My goal is to provide patients with the most advanced and minimally invasive treatment options available, while always focusing on compassion and personalized care. I look forward to helping patients improve their urologic health and quality of life.”

Kiani is now accepting new patients at the DHR Health Urology Institute, located at 2603 Michelangelo Drive in Edinburg, and at the DHR Health Specialty Clinic, located at 505 Angelita Dr., Suite 14, in Weslaco. To schedule an appointment in Edinburg, please call (956) 362-8767, or for Weslaco, call (956) 362-3720. DHR Health accepts a variety of health insurance plans, including Medicare and Medicaid. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 
- Advertisement -